Ph+ ALL, defined by the canonical BCR::ABL1 fusion from chromosomal translocation t(9;22) (q34;q11), represents the first paradigmatic example of the successful incorporation of a molecularly targeted therapy in the treatment of ALL [80]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.